开启辅助访问      

英语家园

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索

新冠肺炎药物定价2340美元

发布者: 千缘 | 发布时间: 2020-7-22 01:59| 查看数: 86| 评论数: 0|



COVID-19 Drug to Cost $2340

新冠肺炎药物定价2340美元

Gilead Sciences said Monday it will charge $2,340 for usual treatment of remdesivir, a drug that is used to shorten recovery time for severely ill COVID-19 patients. However, critics have called the price "an outrage" because of the amount taxpayers invested toward its development.

吉利德科学公司周一表示,其将对瑞德西韦的常规治疗收取2340美元,瑞德西韦是用于缩短新冠肺炎重症患者康复时间的药物。然而,批评者称这一定价“骇人听闻”,因为纳税人为该药物的研发投入了大量资金。

The drug maker said Monday that price would be for people covered by government health programs in the United States and other developed countries. For patients with private health insurance, the price would be $3,120. The amount that patients actually pay themselves could be lower.

这家制药商周一表示,该价格针对美国和其他国家的政府医疗项目覆盖的人群。而拥有私人健康保险的患者,治疗费用为3120美元。患者自费的金额可能会更低。

Gilead's chief executive Dan O'Day told the Associated Press, "We're in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic."

吉利德公司的首席执行官丹·奥黛对美联社表示,“在大流行的情况下为新药定价,我们也处于一个未知的领域。”

He added that the company had to price the drug to ensure more people can get them rather than based only on value to patients.

他补充表示,公司对这种药物的定价必须确保更多人可以获得它,而不是只考虑它对患者的价值。

O'Day said the treatments that the company has given to the U.S. and other countries willrun outin about a week. The prices will apply to the drug after that.

奥黛表示,该公司捐赠给美国和其他国家的疗程将会在一周内用完。此后该药物将会按标价收费。

In the U.S., federal health officials have shared the limited supply with states. But the agreement with Gilead will end after September. They said Monday that the U.S. government has received more than 500,000 additional treatments. Gilead will begin production in July to supply hospitals through September.

美国联邦卫生官员已将该药物的有限供应分配给各州。但政府与吉利德公司的协议将在9月后到期。他们周一表示,美国政府已经收到了超过50万个额外疗程。吉利德公司将于7月开始生产,向医院提供供应直到9月底。

O'Day said there will be enough supply of remdesivir. He added, "but we have to make sure it's in the right place at the right time."

奥黛表示,瑞德西韦应该有充足的供应。他补充说,“但我们必须确保它在正确的时间出现在正确的地点。”

In 127 poor or middle-income countries, Gilead is permitting other drug makers to supply the drug. Two countries are doing that for about $600 for each treatment.

在127个贫穷或中等收入国家,吉利德允许其他制药商供应该药物。目前已经有两个国家这样做,每个疗程需要大约600美元。

Remdesivir became the first medicine to show benefit in treating COVID-19. The disease has killed more than 500,000 people worldwide in six months.

瑞德西韦成为第一个在新冠肺炎治疗中显示出效益的药物。6个月以来,新冠肺炎已在全球造成超过50万人死亡。

Remdesivir restricts the coronavirus's ability to copy its genetic material. In a U.S. government-led study, the drug shortened recovery time by 31 percent. Patients recovered in 11 dayson averageversus 15 days for those given just usual care. It had not improved survival according to early results after two weeks of follow-up. Results after four weeks are expected soon.

瑞德西韦可以限制新冠病毒复制其遗传物质的能力。在美国政府主导的一项研究中,瑞德西韦将患者的恢复时间缩短了31%。使用该药物患者的平均康复时间为11天,而接受常规治疗患者的平均康复时间为15天。经两周的随访,初步结果显示瑞德西韦并不能改善生存率。四周随访的结果很快就会公布。

The Institute for Clinical and Economic Review is a nonprofit group that studies drug prices. The group said remdesivir would be cost-effective between $4,580 and $5,080 if it saved lives. But recent news that a less costly drug called dexamethasone improves survival means remdesivir should be priced between $2,520 and $2,800.

临床与经济评论协会是研究药品价格的的非营利组织。该组织表示,如果瑞德西韦能够挽救生命,它的定价可以在4580美元到5080美元之间。但最近有消息称,一种名为地塞米松的廉价药物可以提高存活率,这意味着瑞德西韦的价格应该定在2520美元到2800美元之间。

"This is a high price for a drug that has not been shown to reduce mortality," Dr. Steven Nissen of the Cleveland Clinic said in an email. "Given the serious nature of the pandemic, I would prefer that the governmenttake overproduction and distribute the drugfor free."

克利夫兰诊所的史蒂文·尼森博士在电邮中表示,“对于一种尚未证明能降低死亡率的药物来说,这个价格太高。考虑到这场大流行的严重性,我希望政府接管生产并免费分发这种药物。”

Peter Maybarduk is a lawyer at the consumer group Public Citizen. He called the price "an outrage."

彼得·梅巴杜克是消费者组织“公共公民”的律师。他称这一价格“骇人听闻”。

"This is a drug that received at least $70 million" from the government toward its development, he said. "Remdesivir should be in the public domain."

他表示,这种药物至少从政府获得了7000万美元的研发资金。“瑞德西韦应该应用于公共领域。”

Gilead says it will have spent $1 billion on developing and making the drug by the end of this year.

吉利德公司表示,到今年年底,该公司将在研发和生产这种药物上花费10亿美元。

The drug can be used for emergencies in the U.S., and Gilead has asked for full approval.

该药物在美国可用于紧急情况,吉利德已获得全面批准。

I'm Jonathan Evans.

乔纳森·埃文斯报道。



最新评论

快速回复 返回顶部 返回列表